HC Wainwright Forecasts OmniAb’s Q1 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of OmniAb in a research report issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million during the quarter, compared to analyst estimates of $10.13 million. During the same quarter in the previous year, the business earned ($0.14) earnings per share.

Separately, Benchmark dropped their target price on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, March 20th.

OmniAb Trading Down 3.9 %

OABI opened at $2.44 on Monday. The business’s fifty day simple moving average is $3.31 and its 200-day simple moving average is $3.74. The company has a market capitalization of $344.57 million, a price-to-earnings ratio of -3.94 and a beta of -0.14. OmniAb has a 12-month low of $2.23 and a 12-month high of $5.54.

Institutional Investors Weigh In On OmniAb

A number of large investors have recently modified their holdings of OABI. Hsbc Holdings PLC purchased a new stake in OmniAb during the 4th quarter worth approximately $38,000. Choreo LLC purchased a new stake in shares of OmniAb during the fourth quarter valued at $41,000. Rangeley Capital LLC acquired a new position in shares of OmniAb in the 4th quarter valued at $41,000. KLP Kapitalforvaltning AS purchased a new position in OmniAb in the 4th quarter worth $49,000. Finally, Walleye Capital LLC acquired a new stake in OmniAb during the 3rd quarter worth about $61,000. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Insider Activity at OmniAb

In other news, CFO Kurt A. Gustafson sold 7,255 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total transaction of $26,625.85. Following the transaction, the chief financial officer now directly owns 206,211 shares of the company’s stock, valued at approximately $756,794.37. This represents a 3.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Charles S. Berkman sold 25,489 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now owns 343,190 shares of the company’s stock, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,260 shares of company stock valued at $376,601 over the last quarter. 8.60% of the stock is owned by corporate insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.